Tech Company Financing Transactions

ITM Isotope Technologies Funding Round

Temasek, Athos Capital and BlackRock participated in a $201 million capital raise for ITM Isotope Technologies. The funding round was announced on 6/6/2024.

Transaction Overview

Announced On
6/6/2024
Transaction Type
Venture Equity
Amount
$201,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to advance and expand its radiopharmaceutical pipeline, foster its development platform and prepare commercial readiness for the potential market launch of its phase III lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Funds will also enable expansion of manufacturing capabilities for the production of alpha- and beta-emitting radioisotopes, including Lutetium-177(177Lu) and Actinium-225(225Ac).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Walther-von-Dyck-Strasse 4
Garching / Munich, 85748
Germany
Email Address
Overview
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Profile
ITM Isotope Technologies LinkedIn Company Profile
Social Media
ITM Isotope Technologies Company Twitter Account
Company News
ITM Isotope Technologies News
Facebook
ITM Isotope Technologies on Facebook
YouTube
ITM Isotope Technologies on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Steffen Schuster
  Steffen Schuster LinkedIn Profile  Steffen Schuster Twitter Account  Steffen Schuster News  Steffen Schuster on Facebook
Chief Financial Officer
Klaus Maleck
  Klaus Maleck LinkedIn Profile  Klaus Maleck Twitter Account  Klaus Maleck News  Klaus Maleck on Facebook
Chief Medical Officer
Danielle Meyrick
  Danielle Meyrick LinkedIn Profile  Danielle Meyrick Twitter Account  Danielle Meyrick News  Danielle Meyrick on Facebook
Chief Operating Officer
Mark Harfensteller
  Mark Harfensteller LinkedIn Profile  Mark Harfensteller Twitter Account  Mark Harfensteller News  Mark Harfensteller on Facebook
Chief Scientific Officer
Konstantin Zhernosekov
  Konstantin Zhernosekov LinkedIn Profile  Konstantin Zhernosekov Twitter Account  Konstantin Zhernosekov News  Konstantin Zhernosekov on Facebook
General Manager
Roger Estafanos
  Roger Estafanos LinkedIn Profile  Roger Estafanos Twitter Account  Roger Estafanos News  Roger Estafanos on Facebook
VP - Bus. Development
Sebastian Marx
  Sebastian Marx LinkedIn Profile  Sebastian Marx Twitter Account  Sebastian Marx News  Sebastian Marx on Facebook
VP - Human Resources
Andrea Schwarz-Dyminski
  Andrea Schwarz-Dyminski LinkedIn Profile  Andrea Schwarz-Dyminski Twitter Account  Andrea Schwarz-Dyminski News  Andrea Schwarz-Dyminski on Facebook
VP - Regulatory Affairs
Gabriele Elbl
  Gabriele Elbl LinkedIn Profile  Gabriele Elbl Twitter Account  Gabriele Elbl News  Gabriele Elbl on Facebook
VP - Regulatory Affairs
Wolfgang Seidel
  Wolfgang Seidel LinkedIn Profile  Wolfgang Seidel Twitter Account  Wolfgang Seidel News  Wolfgang Seidel on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/6/2024: PPC.io venture capital transaction
Next: 6/6/2024: Eyebot venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary